Overview
- Under the agreement, the companies will co-develop IBI363 globally with U.S. co-commercialization led by Takeda, a 40/60 cost share, a 40/60 U.S. profit or loss split, and Takeda holding commercialization rights outside Greater China and the U.S.
- Takeda secured exclusive rights to IBI343 outside Greater China and plans to advance it in first-line gastric and pancreatic settings, building on a China/Japan Phase 3 program plus U.S. Fast Track and China Breakthrough designations.
- Innovent granted Takeda an exclusive option to license IBI3001 outside Greater China.
- IBI363, a PD-1/IL-2α-biased bispecific, is slated to enter a global Phase 3 in second-line squamous non-small cell lung cancer in the coming months and has Breakthrough designation in China with Fast Track in the U.S.
- Innovent will receive $1.2 billion upfront, including a $100 million equity subscription at HK$112.56 per share, and remains eligible for up to $10.2 billion in development and sales milestones plus tiered royalties outside Greater China.